Jump to content
  • Dossier Advanced therapy medicinal products

    Novel gene and cell therapies are associated with high expectations in the treatment of incurable and hereditary diseases. Among them, CAR-T cell therapies have emerged as a major hope in cancer treatment.
    © BIOPRO Baden-Württemberg GmbH

  • Contact Stay in touch

    Would you like continue receiving e-mail notifications about our activities, up-to-date information, events, opportunities for cooperation and general industry information? Register here to stay informed about current issues.
    © denisismagilov / Adobe Stock

  • Industry report The healthcare industry in Baden-Württemberg

    BIOPRO's new report entitled "Healthcare Industry 2020: Facts and Figures for Baden-Württemberg" illustrates key figures like num the number of companies, number of employees and taxable turnover for the biotechnology, medical technology and pharmaceutical industry.
    © MR.LIGHTMAN / Adobe Stock


Latest news

  • Press release - 14/03/2024

    Does our therapeutic approach work against cancer? The answer to this question can make the difference between life and death - and is still difficult to answer. A team from the NMI Natural and Medical Sciences Institute at the University of Tübingen and the Werner Siemens Imaging Center Tübingen has developed a technique for observing immune cells.

  • Press release - 14/03/2024

    Making a personalised T cell therapy for cancer patients currently takes at least six months; scientists at the German Cancer Research Center (DKFZ) and the University Medical Center Mannheim have shown that the laborious first step of identifying tumor-reactive T cell receptors for patients can be replaced with a machine learning classifier that halves this time.

  • Press release - 14/03/2024

    The results of a Tuebingen-led study raise hope that a newly developed drug could herald a new era in oncological liver surgery and transplantation. The drug could even have the potential to significantly improve the treatment of acute and chronic liver diseases. The drug candidate "HRX-215" is a so-called MKK4 inhibitor, i.e. the drug inhibits the MKK4 protein found in liver cells and thus leads to an increase in the regeneration of…

  • Stem cell research - 14/03/2024

    Prof. Dr. Alexander Kleger carries out translational research at Ulm University Hospital to gain a better understanding of pancreatic ductal adenocarcinoma (PDAC) and develop individualised treatments. He and his team are using organoid models and stem cell-based systems and have succeeded in simultaneously cultivating all three main cell types of the pancreas from pluripotent stem cells.

  • Press release - 13/03/2024

    More than seven million people in Germany suffer from diabetes. At the same time, research into drugs to treat this widespread disease is still difficult. Scientists led by Prof. Dr. Peter Loskill from the NMI Natural and Medical Sciences Institute and the Faculty of Medicine of the Eberhard Karls University of Tübingen have now developed a technique that significantly improves the view at the molecular and cell biological level in the pancreas.

Website address: https://www.gesundheitsindustrie-bw.de/en